Research location
Kiyose
Japan
Advertisement
Research activity in Kiyose
JapanCureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 11 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Kiyose
8 linked trials · page 1 of 1Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypeNCT07190209 · 2025-09-16 · 1 site observation
RECRUITING
Tezepelumab PRO StudyNCT05922891 · 2023-09-27 · 1 site observation
COMPLETED
The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)NCT04818983 · 2021-04-07 · 1 site observation
COMPLETED
Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)NCT04501497 · 2020-08-21 · 2 site observations
COMPLETED
A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)NCT03645330 · 2018-08-15 · 2 site observations
COMPLETED
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT01202188 · 2010-09-01 · 1 site observation
COMPLETED
Survey on PD Patients With Depressive SymptomsNCT00614575 · 2007-01-01 · 2 site observations
COMPLETED
Special Survey on Parkinson's Disease Patients Treated Long-term Use of PramipexoleNCT00615914 · 2004-02-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.